CASMED Submits FORE-SIGHT® OEM Module 510(k) to FDA

CAS Medical Systems (NASDAQ:CASM) a leader in non-invasive cerebral oximetry patient monitoring, announces that it has submitted a 510(k) application to the U.S. Food and Drug Administration for the FORE-SIGHT Tissue Oximetry OEM Module, an OEM version of its FORE-SIGHT ELITE® Tissue Oximeter.
As quoted in the press release:

“This filing is a major milestone for CASMED as we seek to make our best-in-class FORE-SIGHT oximetry technology available to manufacturers of other monitoring equipment,” said Thomas M. Patton, President and Chief Executive Officer of CASMED. “By partnering with third-party monitoring companies to incorporate FORE-SIGHT oximetry technology through the OEM Module, CASMED can leverage their selling resources to more quickly expand the market for tissue oximetry and gain market share.

Click here to read the full press release.